ArticleCommunications biology2025
Integrated methylome analysis identifies an epigenetically silenced tumor suppressor RASA4 in small cell lung cancer.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Small cell lung cancer (SCLC) is highly lethal, often developing rapid chemo-resistance and progression after initial response to platinum-based chemotherapy. The role of DNA methylation in driving this progression remains poorly understood. Here, genome-wide methylation profiling via methylated DNA immuno-precipitation sequencing (MeDIP-seq) reveals hypermethylated and hypomethylated regions in both SCLC tissue DNA and plasma cell free DNA (cfDNA). A hypermethylated region in the promoter of RASA4 gene, common to SCLC tumor DNA and progression-associated cfDNA, is identified. Pharmacologic and, more specifically, targeted demethylation reactivate RASA4 expression in SCLC. The down-regulation of RASA4, a negative regulator of Ras signal, leads to the activation of Ras-MAPK pathway in SCLC. RASA4 overexpression inhibits SCLC growth, invasion and chemo-resistance, whereas its knockdown promotes these malignant phenotypes by enhancing epithelial-mesenchymal transition (EMT) and stemness. We further demonstrate that RASA4 negatively regulates the EMT-related protein SERPINE2, and directly interacts with it. Immunohistochemistry analysis of clinical specimens validates that RASA4 is significantly down-regulated in SCLC tumors, and its low expression correlates with SCLC patients' poor survival. Taken together, the epigenetic silencing of RASA4 drives SCLC progression through the induction of EMT and stemness. Our findings underscore the potential of RASA4 as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.